{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:25:20Z","timestamp":1787779520742,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Beijing Municipal Administration of Hospitals Incubating Program","award":["PX2022007"],"award-info":[{"award-number":["PX2022007"]}]},{"name":"the primary scientific research foundation for the junior researcher in Beijing Tongren Hospital, Capital Medical University","award":["2020-YJJ-ZZL-011"],"award-info":[{"award-number":["2020-YJJ-ZZL-011"]}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2020-2-1081"],"award-info":[{"award-number":["2020-2-1081"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071000"],"award-info":[{"award-number":["82071000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Beijing Science Foundation for Distinguished Yong Scholars","award":["JQ20029"],"award-info":[{"award-number":["JQ20029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the effect of low-dose atropine eyedrops on pupil metrics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study was based on a randomized, double-masked, placebo-controlled, and cross-over trial in mainland China. In phase 1, subjects received 0.01% atropine or placebo once nightly. After 1\u00a0year, the atropine group switched to placebo (atropine-placebo group), and the placebo group switched to atropine (placebo-atropine group). Ocular parameters were measured at the crossover time point (at the 12th month) and the 18th month.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 105 subjects who completed the study, 48 and 57 children were allocated into the atropine-placebo and placebo-atropine groups, respectively. After cessation, the photopic pupil diameter (PD) and mesopic PD both decreased (\u2212\u20090.46\u2009\u00b1\u20090.47\u00a0mm, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001;\u2009\u2212\u20090.30\u2009\u00b1\u20090.74\u00a0mm, <jats:italic>P<\/jats:italic>\u2009=\u20090.008), and the constriction ratio (CR, %) increased (4.39\u2009\u00b1\u20097.54, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared with values at the crossover time point of the atropine-placebo group; pupil metrics of the atropine-placebo group had no difference from the values at the crossover time point of the placebo-atropine group. After 6\u00a0months of treatment, the photopic PD and the mesopic PD increased (0.54\u2009\u00b1\u20090.67\u00a0mm, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; 0.53\u2009\u00b1\u20090.89\u00a0mm, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), the CR (%) decreased (\u2212\u20092.53\u2009\u00b1\u20098.64, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared with values at the crossover time point of the placebo-atropine group. There was no significant relationship between pupil metrics and myopia progression during 0.01% atropine treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pupil metrics and the CR could return to pre-atropine levels after cessation. Pupil metrics had no significant effect on myopia progression during treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00417-022-05863-8","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T09:03:59Z","timestamp":1668848639000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of low-dose atropine eyedrops on pupil metrics: results after half a year of treatment and cessation"],"prefix":"10.1007","volume":"261","author":[{"given":"Wei-Ling","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-He","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zai","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Tong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-4482","authenticated-orcid":false,"given":"Ningli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"5863_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith Iii EL, Zhou X, Matsui KO, Wu PC, Sankaridurg P, Chia A, Rosman M, Lamoureux EL, Man R, He M (2020) Myopia Nature Rev Disease Prim 6:99. https:\/\/doi.org\/10.1038\/s41572-020-00231-4","journal-title":"Myopia Nature Rev Disease Prim"},{"key":"5863_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123:1036\u20131042. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006","journal-title":"Ophthalmol"},{"key":"5863_CR3","doi-asserted-by":"publisher","unstructured":"Chen X, Xiong Y, Liu F, Wang J, Yang B, Liu L (2022) Factors determining the myopia control effect of an orthokeratology lens: a two-year multi-level model. Ophthalmic & physiological optics: J Br College Ophthalmic Optic (Optometrists).\u00a0\u00a0https:\/\/doi.org\/10.1111\/opo.12990","DOI":"10.1111\/opo.12990"},{"key":"5863_CR4","doi-asserted-by":"publisher","unstructured":"Fricke TR, Sankaridurg P, Naduvilath T, Resnikoff S, Tahhan N, He M, Frick KD (2022) Establishing a method to estimate the effect of antimyopia management options on lifetime cost of myopia. Br J Ophthalmol.\u00a0\u00a0https:\/\/doi.org\/10.1136\/bjophthalmol-2021-320318","DOI":"10.1136\/bjophthalmol-2021-320318"},{"key":"5863_CR5","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.clae.2021.101530","volume":"45","author":"J Gispets","year":"2022","unstructured":"Gispets J, Y\u00e9bana P, Lup\u00f3n N, Cardona G, P\u00e9rez-Corral J, Paun\u00e9 J, Cortilla B (2022) Efficacy, predictability and safety of long-term orthokeratology: an 18-year follow-up study. Cont Lens Anterior Eye: J Br Contact Lens Assoc 45:101530. https:\/\/doi.org\/10.1016\/j.clae.2021.101530","journal-title":"Contact lens & anterior eye: J Br Contact Lens Assoc"},{"key":"5863_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","volume":"62","author":"JB Jonas","year":"2021","unstructured":"Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, Logan NS, Liu M, Morgan I, Ohno-Matsui K, P\u00e4rssinen O, Resnikoff S, Sankaridurg P, Saw SM, Smith EL 3rd, Tan DTH, Walline JJ, Wildsoet CF, Wu PC, Zhu X, Wolffsohn JS (2021) IMI Prevention of Myopia and its progression. Invest Ophthalmol Vis Sci 62:6. https:\/\/doi.org\/10.1167\/iovs.62.5.6","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5863_CR7","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1167\/iovs.14-15474","volume":"56","author":"SM Li","year":"2015","unstructured":"Li SM, Li H, Li SY, Liu LR, Kang MT, Wang YP, Zhang F, Zhan SY, Gopinath B, Mitchell P, Wang N (2015) Time outdoors and myopia progression over 2 years in Chinese children: the Anyang childhood eye study. Invest Ophthalmol Vis Sci 56:4734\u20134740. https:\/\/doi.org\/10.1167\/iovs.14-15474","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5863_CR8","doi-asserted-by":"publisher","unstructured":"Wei S, Li S-M, An W, Du J, Liang X, Sun Y, Zhang D, Tian J, Wang N (2020) Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol.\u00a0\u00a0https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3820","DOI":"10.1001\/jamaophthalmol.2020.3820"},{"key":"5863_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua W-H, Cheung Y-B, Wong W-L, Lingham A, Fong A, Tan D (2012) Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the treatment of myopia 2). Ophthalmology 119:347\u2013354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031","journal-title":"Ophthalmol"},{"key":"5863_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP (2019) Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126:113\u2013124. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029","journal-title":"Ophthalmol"},{"key":"5863_CR11","doi-asserted-by":"publisher","unstructured":"Tsai HR, Chen TL, Wang JH, Huang HK, Chiu CJ (2021) Is 0.01% Atropine an effective and safe treatment for myopic children? a systemic review and meta-analysis. J Clin Med 10.\u00a0https:\/\/doi.org\/10.3390\/jcm10173766","DOI":"10.3390\/jcm10173766"},{"key":"5863_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D (2016) Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology 123:391\u2013399. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.004","journal-title":"Ophthalmology"},{"key":"5863_CR13","doi-asserted-by":"publisher","first-page":"21748","DOI":"10.1038\/s41598-021-00923-1","volume":"11","author":"I P\u00e9rez-Flores","year":"2021","unstructured":"P\u00e9rez-Flores I, Mac\u00edas-Murelaga B, Barrio-Barrio J (2021) A multicenter Spanish study of atropine 0 01% in childhood myopia progression. Sci Rep 11:21748. https:\/\/doi.org\/10.1038\/s41598-021-00923-1","journal-title":"Sci Rep"},{"key":"5863_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","volume":"8","author":"GL Larkin","year":"2019","unstructured":"Larkin GL, Tahir A, Epley KD, Beauchamp CL, Tong JT, Clark RA (2019) Atropine 0.01% eye drops for myopia control in American children: a multiethnic sample across three US sites. Ophthalmol Therapy 8:589\u2013598. https:\/\/doi.org\/10.1007\/s40123-019-00217-w","journal-title":"Ophthalmol Therapy"},{"key":"5863_CR15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1136\/bjophthalmol-2015-307861","volume":"100","author":"J Loughman","year":"2016","unstructured":"Loughman J, Flitcroft DI (2016) The acceptability and visual impact of 0.01% atropine in a Caucasian population. Br J Ophthalmol 100:1525\u20131529. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307861","journal-title":"Br J Ophthalmol"},{"key":"5863_CR16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/opx.0000000000000037","volume":"90","author":"J Cooper","year":"2013","unstructured":"Cooper J, Eisenberg N, Schulman E, Wang FM (2013) Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 90:1467\u20131472. https:\/\/doi.org\/10.1097\/opx.0000000000000037","journal-title":"Optom Vis Sci"},{"key":"5863_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH (2022) Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis. Ophthalmology 129:322\u2013333. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.016","journal-title":"Ophthalmology"},{"key":"5863_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP (2022) Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology 129:308\u2013321. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.002","journal-title":"Ophthalmol"},{"key":"5863_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/bjophthalmol-2019-315440","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, Ji N, Lyu Y (2020) Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol 104:1535\u20131541. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315440","journal-title":"Br J Ophthalmol"},{"key":"5863_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP (2020) Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology 127:910\u2013919. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.011","journal-title":"Ophthalmol"},{"key":"5863_CR21","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1097\/OPX.0b013e31826c1831","volume":"89","author":"Z Chen","year":"2012","unstructured":"Chen Z, Niu L, Xue F, Qu X, Zhou Z, Zhou X, Chu R (2012) Impact of pupil diameter on axial growth in orthokeratology. Optom Vis Sci 89:1636\u20131640. https:\/\/doi.org\/10.1097\/OPX.0b013e31826c1831","journal-title":"Optom Vis Sci"},{"key":"5863_CR22","first-page":"545","volume":"14","author":"JS Fosnaugh","year":"1992","unstructured":"Fosnaugh JS, Bunker EB, Pickworth WB (1992) Daily variation and effects of ambient light and circadian factors on the human light reflex. Methods Find Exp Clin Pharmacol 14:545\u2013553","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"5863_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnint.2017.00006","volume":"11","author":"LY-L Chang","year":"2017","unstructured":"Chang LY-L, Turuwhenua J, Qu TY, Black JM, Acosta ML (2017) Infrared video pupillography coupled with smart phone LED for measurement of pupillary light reflex. Front Integr Neurosci 11:6. https:\/\/doi.org\/10.3389\/fnint.2017.00006","journal-title":"Front Integr Neurosci"},{"key":"5863_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, Du J, Liang X, Sun Y, Zhang D, Tian J, Wang N (2020) Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol 138:1178\u20131184. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3820","journal-title":"JAMA Ophthalmol"},{"key":"5863_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/ijg.0000000000001183","volume":"28","author":"DS Chang","year":"2019","unstructured":"Chang DS, Arora K, Boland MV, Friedman DS (2019) The relationship between quantitative pupillometry and estimated ganglion cell counts in patients with glaucoma. J Glaucoma 28:238\u2013242. https:\/\/doi.org\/10.1097\/ijg.0000000000001183","journal-title":"J Glaucoma"},{"key":"5863_CR26","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00417-018-4112-8","volume":"256","author":"H Kaymak","year":"2018","unstructured":"Kaymak H, Fricke A, Mauritz Y, L\u00f6winger A, Klabe K, Breyer D, Lagenbucher A, Seitz B, Schaeffel F (2018) Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects. Graefes Arch Clin Exp Ophthalmol 256:2211\u20132217. https:\/\/doi.org\/10.1007\/s00417-018-4112-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5863_CR27","doi-asserted-by":"publisher","unstructured":"Myles W, Dunlop C, McFadden SA (2021) The effect of long-term low-dose atropine on refractive progression in myopic Australian school children. J Clin Med 10.\u00a0\u00a0https:\/\/doi.org\/10.3390\/jcm10071444","DOI":"10.3390\/jcm10071444"},{"key":"5863_CR28","unstructured":"Yen MY, Liu JH, Kao SC, Shiao CH (1989) Comparison of the effect of atropine and cyclopentolate on myopia. Ann Ophthalmol 21(5):180\u20132:187"},{"key":"5863_CR29","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","volume":"124","author":"SL Pineles","year":"2017","unstructured":"Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, Lambert SR (2017) Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology. Ophthalmology 124:1857\u20131866. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.032","journal-title":"Ophthalmol"},{"key":"5863_CR30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D (2006) Atropine for the treatment of childhood myopia. Ophthalmology 113:2285\u20132291. https:\/\/doi.org\/10.1016\/j.ophtha.2006.05.062","journal-title":"Ophthalmol"},{"key":"5863_CR31","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","volume":"11","author":"C Cui","year":"2021","unstructured":"Cui C, Li X, Lyu Y, Wei L, Zhao B, Yu S, Rong J, Bai Y, Fu A (2021) Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep 11:22267. https:\/\/doi.org\/10.1038\/s41598-021-01708-2","journal-title":"Sci Rep"},{"key":"5863_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, Ishiko S, Hasebe S, Torii H, Takahashi H, Nakamura Y, Sotozono C, Oshika T, Morimoto T, Nishida K, Nishikawa N, Song YS, Tokutake T, Nishi Y, Shigeno Y, Kurihara T, Negishi K, Tsubota K, Ono M, Nakai T, Tan D, Tanaka S, Kinoshita S (2021) Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol 65:315\u2013325. https:\/\/doi.org\/10.1007\/s10384-021-00822-y","journal-title":"Jpn J Ophthalmol"},{"key":"5863_CR33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","volume":"128","author":"R Saxena","year":"2021","unstructured":"Saxena R, Dhiman R, Gupta V, Kumar P, Matalia J, Roy L, Swaminathan M, Phuljhele S, Velpandian T, Sharma N (2021) Atropine for the treatment of childhood myopia in India: multicentric randomized trial. Ophthalmology 128:1367\u20131369. https:\/\/doi.org\/10.1016\/j.ophtha.2021.01.026","journal-title":"Ophthalmol"},{"key":"5863_CR34","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D (2014) Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 157:451-457.e451. https:\/\/doi.org\/10.1016\/j.ajo.2013.09.020","journal-title":"Am J Ophthalmol"},{"key":"5863_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7150\/ijms.39365","volume":"17","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Tang Y, Guo L, Tighe S, Zhou Y, Zhang X, Zhang J, Zhu Y, Hu M (2020) Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children. Int J Med Sci 17:176\u2013181. https:\/\/doi.org\/10.7150\/ijms.39365","journal-title":"Int J Med Sci"},{"key":"5863_CR36","doi-asserted-by":"publisher","first-page":"11729","DOI":"10.1038\/s41598-021-88719-1","volume":"11","author":"A Fu","year":"2021","unstructured":"Fu A, Stapleton F, Wei L, Wang W, Zhao B, Watt K, Yu S, Cui C, Lyu Y (2021) Risk factors for rapid axial length elongation with low concentration atropine for myopia control. Sci Rep 11:11729. https:\/\/doi.org\/10.1038\/s41598-021-88719-1","journal-title":"Sci Rep"},{"key":"5863_CR37","doi-asserted-by":"publisher","unstructured":"Michalski A, Rogaczewska M, Maleszka-Kurpiel M, Stopa M (2020) Pharmacological myopia control influence on quality of life and psyche among adolescents. J Clin Med 9.\u00a0\u00a0https:\/\/doi.org\/10.3390\/jcm9123920","DOI":"10.3390\/jcm9123920"},{"key":"5863_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1097\/OPX.0000000000000034","volume":"90","author":"J Santodomingo-Rubido","year":"2013","unstructured":"Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Guti\u00e9rrez-Ortega R (2013) Factors preventing myopia progression with orthokeratology correction. Optom Vis Sci 90:1225\u20131236. https:\/\/doi.org\/10.1097\/OPX.0000000000000034","journal-title":"Optom Vis Sci"},{"key":"5863_CR39","doi-asserted-by":"publisher","unstructured":"Zhou H, Zhao G, Li Y (2021) Adjunctive effects of orthokeratology and atropine 0.01% eye drops on slowing the progression of myopia. Clinic Exp Optom: 1\u20137.\u00a0\u00a0https:\/\/doi.org\/10.1080\/08164622.2021.1943318","DOI":"10.1080\/08164622.2021.1943318"},{"key":"5863_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/00006324-199808000-00027","volume":"75","author":"LC Woung","year":"1998","unstructured":"Woung LC, Lue YF, Shih YF (1998) Accommodation and pupillary response in early-onset myopia among schoolchildren. Optom Vis Sci 75:611\u2013616","journal-title":"Optom Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-022-05863-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-022-05863-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T07:09:46Z","timestamp":1679987386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-022-05863-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5863"],"URL":"https:\/\/doi.org\/10.1007\/s00417-022-05863-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"29 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board of Beijing Tongren Hospital, Capital Medical University and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The trial was registered on the Chinese Clinical Trial Registry (). The registration number is ChiCTR-IOR-17013898.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}